LexisNexis® Legal Newsroom
$8M Fosamax Verdict Remitted By MDL Judge To $1.5M Or New Damages Trial

NEW YORK -- (Mealey's) The New York federal judge overseeing the Fosamax multidistrict litigation on Oct. 4 sua sponte found that an $8 million verdict in a bellwether trial is excessive and ordered a remittitur of the verdict to $1.5 million unless plaintiff Shirley Boles wants a new trial on damages...

Fosamax MDL Jury: Drug Wasn't Defectively Designed, Didn't Cause Jaw Injury

NEW YORK - A New York federal jury hearing the fourth Fosamax bellwether trial on Oct. 3 found that Merck's osteoporosis drug was not defectively designed and did not cause a plaintiff to develop osteonecrosis of the jaw (ONJ) ( In Re: Fosamax Products Liability Litigation , MDL Docket No. 1789,...

Merck To Settle Suits Alleging Jaw Damage From Osteoporosis Drug

WHITEHOUSE STATION, N.J. — (Mealey's) Merck & Co. Inc. has agreed to pay $27.7 million to resolve product liability suits alleging that its osteoporosis drug Fosamax caused osteonecrosis of the jaw (ONJ), or bone death, according to a press release the company issued Dec. 9 ( In Re: Fosamax...